Masonic Medical Research Laboratory, Utica, New York 13501, USA.
Heart Rhythm. 2012 Mar;9(3):422-9. doi: 10.1016/j.hrthm.2011.10.021. Epub 2011 Oct 20.
Vernakalant (VER) is a relatively atrial-selective antiarrhythmic drug capable of blocking potassium and sodium currents in a frequency- and voltage-dependent manner. Ranolazine (RAN) is a sodium-channel blocker shown to exert antiarrhythmic effects in pulmonary vein (PV) sleeves. dl-Sotalol (SOT) is a β-blocker commonly used in the rhythm-control treatment of atrial fibrillation. This study evaluated the electrophysiological and antiarrhythmic effects of VER, RAN, and SOT in canine PV sleeve preparations in a blinded fashion.
Transmembrane action potentials were recorded from canine superfused PV sleeve preparations exposed to VER (n = 6), RAN (n = 6), and SOT (n = 6). Delayed afterdepolarizations were induced in the presence of isoproterenol and high-calcium concentrations by periods of rapid pacing.
In PV sleeves, VER, RAN, and SOT (3-30 μM) produced small (10-15 ms) increases in action potential duration. The effective refractory period, diastolic threshold of excitation, and the shortest S(1)-S(1) cycle length permitting 1:1 activation were significantly increased by VER and RAN in a rate- and concentration-dependent manner. VER and RAN significantly reduced V(max) in a concentration- and rate-dependent manner. SOT did not significantly affect the effective refractory period, V(max), diastolic threshold of excitation, or the shortest S(1)-S(1) cycle length permitting 1:1 activation. All 3 agents (3-30 μM) suppressed delayed afterdepolarization-mediated triggered activity induced by isoproterenol and high calcium.
In canine PV sleeves, the effects of VER and RAN were similar and largely characterized by concentration- and rate-dependent depression of sodium-channel-mediated parameters, which were largely unaffected by SOT. All 3 agents demonstrated an ability to effectively suppress delayed afterdepolarization-induced triggers of atrial arrhythmia.
维纳卡兰(VER)是一种相对心房选择性抗心律失常药物,能够以频率和电压依赖的方式阻断钾和钠电流。雷诺嗪(RAN)是一种钠通道阻滞剂,已被证明在肺静脉(PV)袖套中具有抗心律失常作用。dl-索他洛尔(SOT)是一种常用于心房颤动节律控制治疗的β受体阻滞剂。本研究以盲法方式评估了 VER、RAN 和 SOT 在犬 PV 袖套标本中的电生理和抗心律失常作用。
将 VER(n = 6)、RAN(n = 6)和 SOT(n = 6)暴露于犬超射 PV 袖套标本中,记录跨膜动作电位。在异丙肾上腺素和高钙浓度存在下,通过快速起搏期诱导延迟后除极。
在 PV 袖套中,VER、RAN 和 SOT(3-30 μM)使动作电位时程增加 10-15ms。VER 和 RAN 以剂量和频率依赖性方式显著增加有效不应期、舒张阈值兴奋和允许 1:1 激活的最短 S1-S1 周期长度。VER 和 RAN 以浓度和频率依赖性方式显著降低 Vmax。SOT 对有效不应期、Vmax、舒张阈值兴奋或允许 1:1 激活的最短 S1-S1 周期长度没有显著影响。所有 3 种药物(3-30 μM)均抑制异丙肾上腺素和高钙诱导的延迟后除极介导的触发活动。
在犬 PV 袖套中,VER 和 RAN 的作用相似,主要表现为浓度和频率依赖性钠通道介导参数的抑制,而 SOT 对其影响不大。所有 3 种药物均具有有效抑制延迟后除极诱导的心房心律失常触发的能力。